Preparations methods of tizanidine (API) and related compounds: A review

Korany A. Ali, Eman Ali Ragab

Article ID: 1771
Vol 6, Issue 1, 2023

VIEWS - 504 (Abstract) 608 (PDF)

Abstract


Tizanidine is an imidazoline derivative with the agonistic activity of central alpha 2 receptors at both the spinal and supra-spinal levels. It was prepared for the first time in 1978 and approved for use in 1996. The present review focuses on all methods used for the synthesis of tizanidine, related compounds and intermediates. This review article covers all the methods that have been used in the preparation of tizanidine since its discovery until now. Methods used for the preparation of tizanidine-related compounds are also covered. This review gives those interested in drug synthesis and designs the ability to form a complete picture of the preparation of this drug, as well as providing the opportunity for the synthesis of other drugs developed from this drug to increase activity and/or reduce side effects.

Keywords


Tizanidine; Drug Intermediates; Imidazoline Derivative; Drugs Synthesis

Full Text:

PDF


References


1. Kamen L, Henney HR, Runyan JD. A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury. Current Medical Research and Opinion 2008; 24(2): 425. doi: 10.1185/030079908X261113.

2. Acorda Therapeutics Inc. Zanaflex (tizanidine hydrochloride) capsules and tablets for oral use. Full prescribing information. Ardsley, New York: Acorda Therapeutics Inc.; 2016.

3. Wagstaff AJ, Bryson HM. Tizanidine: A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs 1997; 53: 435–452. doi: 10.2165/00003495-199753030-00007.

4. Drugs.com. Tizanidine hydrochloride monograph for professionals [Internet]. Bethesda (MD): American Society of Health-System Pharmacists, Inc.; 2019 [accessed 2019 Mar 3]. Available from: https://www.drugs.com/monograph/tizanidine-hydrochloride.html.

5. Drugs.com. Tizanidine pregnancy and breastfeeding warnings [Internet]. Bethesda (MD): American Society of Health-System Pharmacists, Inc.; 2019 [accessed 2019 Mar 3]. Available from: https://www.drugs.com/pregnancy/tizanidine.html.

6. ClinCalc LLC. Tizanidine-Drug usage statistics [Internet]. Rockville (MD): Agency for Healthcare Research and Quality; 2021 [accessed 2021 Feb 18]. Available from: https://clincalc.com/DrugStats/Drugs/Tizanidine.

7. Henney HR, Runyan JD. A clinically relevant review of tizanidine hydrochloride dose relationships to pharmacokinetics, drug safety and effectiveness in healthy subjects and patients. International Journal of Clinical Practice 2008; 62(2): 314–324. doi: 10.1111/j.1742-1241.2007.01660.x.

8. Malanga G, Reiter RD, Garay E. Update on tizanidine for muscle spasticity and emerging indications. Expert Opinion on Pharmacotherapy 2008; 9(12): 2209–2215. doi: 10.1517/14656566.9.12.2209.

9. Mathias CJ, Luckitt J, Desai P, et al. Pharmacodynamics and pharmacokinetics of the oral antispastic agent tizanidine in patients with spinal cord injury. Journal of Rehabilitation Research and Development 1989; 26(4): 9.

10. Mense S. Muscle pain: Mechanisms and clinical significance. Deutsches Ärzteblatt 2008; 105(12): 2140. doi: 10.3238/artzebl.2008.0214.

11. Neumann P (inventor). Sandoz AG (assignee). Certain 4-substituted amino-2,1,3-benzothiadiozoles. US patent. 3,843,668. 1974 Oct 22.

12. Neumann P (inventor). Wander Ag Dr A (assignee). Imidazolin-2-ylamino-2,1,3-benzothiadiazoles prodn. - by cyclising corresp. beta aminoethyl (thio) ureas, active against muscle tremors and rigor. CH patent. 579,565. 1976 Sep 15.

13. Liu Q, Fu L, Li X, et al. (inventors). Luzhou Kered Pharmaceutical Co., Ltd, Sichuan Credit Pharmaceutical Co., Ltd. (assignees). Preparation method of novel central skeletal muscle relaxant. Chinese patent. 107,759,582. 2021 Oct 1.

14. Wang K, Fu L, Chen G, et al. (inventors). Sichuan Keruide Pharmaceutical Ltd By Share Ltd (assignee). Process for preparing imidazoline-diazacyclopentene derivatives. Chinese patent. 110,563,715. 2019 Dec 13.

15. Keiji O, Kiyonori Y, Hideki N (inventors). Permachem Asia Ltd (assignee). A process for making a benzothiadiazole derivative. EP patent. 0,644,192. 1996 Dec 18.

16. Hradil P, Kvapil L, Grepl M, Novotný J (inventors). Farmak AS (assignee). Process for preparing tizanidine hydrochloride. Czechia patent. 2,008,819. 2010 Jul 21.

17. Liu Q, Li X, Fu L, et al. (inventors). Sichuan Keruide Pharmaceutical Ltd By Share Ltd (assignee). The preparation method for benzothiadiazole derivative. Chinese patent. 109,535,148. 2019 Mar 29.

18. Liu Q, Fu L, Li X, et al. (inventors). Luzhou Kered Pharmaceutical Co., Ltd, Sichuan Credit Pharmaceutical Co., Ltd. (assignees). A kind of preparation method of the adrenoceptor agonists of central α 2. Chinese patent. 107,778,307. 2021 May 28.

19. Mo D, Wang H, Chen H, et al. Chlorination of low-band-gap polymers: Toward high-performance polymer solar cells. Chemistry of Materials 2017; 29(7): 2819–2830. doi: 10.1021/acs.chemmater.6b04828.

20. Nguyen YH, Lampkin BJ, Venkatesh A, et al. Open-resonance-assisted hydrogen bonds and competing ouasiaromaticity. The Journal of Organic Chemistry 2018; 83(17): 9850–9857. doi: 10.1021/acs.joc.8b01331.

21. Walter T, Smith Jr, Wen-Yean C. Preparation of 2,1,3-benzothiadiazoles using dimethylformamide-sulfur dioxide reagent. The Journal of Organic Chemistry 1962; 27: 676–677. doi: 10.1021/jo01049a536.

22. Zhivotova TS, Gazaliev AM, Fazylov SD, et al. Synthesis and structure of some imidazolidine-2-thiones. Russian Journal of Organic Chemistry 2006; 42(3): 448–450. doi: 10.1134/S1070428006030183.

23. Baer JE, Lockwood RG. Acetylation and S-alkylation of ethylene thiourea. Journal of the American Chemical Society 1954; 76(4): 1162–1164. doi: 10.1021/ja01633a068.

24. Greenhalgh R, Weinberger MA. Nuclear magnetic resonance and infrared studies of acylated imidazolidinones and imidazolidinethiones. Canadian Journal of Chemistry 1965; 43(12): 3340–3346. doi: 10.1139/v65-464.




DOI: https://doi.org/10.24294/ace.v6i1.1771

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.